Endocrine Society GUIDELINES Bundle (free trial)

Paget's Disease of Bone

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1140175

Contents of this Issue

Navigation

Page 3 of 5

Treatment Indications Î The ES recommends treatment with a bisphosphonate (see Table 2) for most patients with active Paget's disease who are at risk of future complications. (1|⊕⊕⊕ ) Choice of Medication Î The ES suggests a single 5-mg dose of IV zoledronate as the treatment of choice in patients without contraindications. (2|⊕⊕⊕ ) Assessing the Response to Treatment Î If there is urgency in the control of symptoms or the disease is particularly active, the ES suggests the use of short-term response of bone resorption markers before and shortly after treatment to indicate that an adequate therapeutic response is likely. (2|⊕⊕ ) Î The ES suggests that patients who have osteolytic lesions of Paget's disease have a repeat x-ray approximately 1 year after radiological diagnosis to determine whether there has been improvement with therapy or worsening in the absence of therapy. Subsequent x-rays may be considered in the event of persistent elevations of biochemical markers of bone turnover or the presence of bone pain and to determine when there is resolution of the lesion. (2|⊕⊕ ) Maintaining Remission Î The ES suggests that to maximize the duration of remission, bone turnover should be reduced below the midpoint of the reference range for the chosen monitoring bone turnover marker. (2|⊕⊕ ) Relapse and Retreatment Î The ES recommends that in patients with increased bone turnover, biochemical follow-up should be used as a more objective indicator of relapse than symptoms. (1|⊕⊕⊕ ) Monostotic Paget's Disease Î The ES suggests that amino-terminal propeptide of type 1 collagen (P1NP) or bone-specific ALP (BSAP) and βC-terminal propeptide of type 1 collagen (βCTx) or N-terminal propeptide of type 1 collagen (NTx) should be used for assessing the activity of untreated monostotic Paget's disease, although these may be normal when evidence of disease activity is still clearly demonstrated on scintigraphy. (2|⊕⊕ )

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Paget's Disease of Bone